Overview

The Efficacy and Safety of OROSARTAN® Versus CODIOVAN® in Patients With Essential Hypertension Uncontrolled With Monotherapy

Status:
Completed

Trial end date:
2016-09-08

Target enrollment:

Participant gender:

Summary

A multi-center, randomized, double-blind, phase IV clinical trial to compare the efficacy and safety of OROSARTAN® tablet 5/160mg versus CODIOVAN® tablet 160/12.5mg in patients with essential hypertension uncontrolled with valsartan 160mg monotherapy

Phase:

Phase 4

Details

Lead Sponsor:

Dong-A ST Co., Ltd.

Treatments:

Amlodipine
Hydrochlorothiazide
Valsartan